BACKGROUND: Patients with a normal stress technetium 99m sestamibi study were shown to have a favorable outcome at intermediate-term follow-up. However, long-term survival has not been studied. The aim of this study was to evaluate the incidence and predictors of mortality and cardiac events at long-term follow-up after a normal exercise stress sestamibi study. Methods and results We studied 218 patients (mean age, 53 +/- 10 years, 108 men) who had normal myocardial perfusion assessed by Tc-99m sestamibi single photon emission computed tomography at rest and during symptom-limited bicycle exercise stress test. Endpoints during a follow-up period of 7.4 +/- 1.8 years were hard cardiac events (cardiac death and nonfatal myocardial infarction) and all-cause mortality. During follow-up, 13 patients died of various causes (cardiac death in 1 patient). Ten patients had nonfatal myocardial infarction (a total of 11 hard cardiac events). By multivariate analysis, independent predictors of cardiac events were history of coronary artery disease (chi(2) = 5, P =.03) and lower exercise heart rate (chi(2) = 12, P =.001). Independent predictors of all-cause mortality were age (chi(2) = 4, P =.05) and exercise heart rate (chi(2) = 5, P =.03). The annual mortality rate was 0.6% in the first 5 years and 1.8% between the sixth and eighth years. The annual hard cardiac event rate was 0.7% in the first 5 years and 1.5% between the sixth and eighth years. Receiver operating characteristic curves identified an exercise heart rate lower than 130 beats/min as the cutoff value that separated patients with regard to their risk for mortality and hard cardiac events. CONCLUSIONS: It is concluded that the annual mortality and cardiac event rate is less than 1% during 5-year follow-up after a normal exercise sestamibi study. Therefore repeated testing would not be required unless there is a change in symptoms. Follow-up should be closer in patients with a history of coronary artery disease and in those who fail to achieve an exercise heart rate of 130 beats/min or greater.
BACKGROUND:Patients with a normal stress technetium 99m sestamibi study were shown to have a favorable outcome at intermediate-term follow-up. However, long-term survival has not been studied. The aim of this study was to evaluate the incidence and predictors of mortality and cardiac events at long-term follow-up after a normal exercise stress sestamibi study. Methods and results We studied 218 patients (mean age, 53 +/- 10 years, 108 men) who had normal myocardial perfusion assessed by Tc-99m sestamibi single photon emission computed tomography at rest and during symptom-limited bicycle exercise stress test. Endpoints during a follow-up period of 7.4 +/- 1.8 years were hard cardiac events (cardiac death and nonfatal myocardial infarction) and all-cause mortality. During follow-up, 13 patients died of various causes (cardiac death in 1 patient). Ten patients had nonfatal myocardial infarction (a total of 11 hard cardiac events). By multivariate analysis, independent predictors of cardiac events were history of coronary artery disease (chi(2) = 5, P =.03) and lower exercise heart rate (chi(2) = 12, P =.001). Independent predictors of all-cause mortality were age (chi(2) = 4, P =.05) and exercise heart rate (chi(2) = 5, P =.03). The annual mortality rate was 0.6% in the first 5 years and 1.8% between the sixth and eighth years. The annual hard cardiac event rate was 0.7% in the first 5 years and 1.5% between the sixth and eighth years. Receiver operating characteristic curves identified an exercise heart rate lower than 130 beats/min as the cutoff value that separated patients with regard to their risk for mortality and hard cardiac events. CONCLUSIONS: It is concluded that the annual mortality and cardiac event rate is less than 1% during 5-year follow-up after a normal exercise sestamibi study. Therefore repeated testing would not be required unless there is a change in symptoms. Follow-up should be closer in patients with a history of coronary artery disease and in those who fail to achieve an exercise heart rate of 130 beats/min or greater.
Authors: A Desideri; G Candelpergher; P Zanco; G Suzzi; R Terlizzi; N Borsato; G Colangeli; C Daskalakis; F Chierichetti; L Celegon Journal: Clin Cardiol Date: 1997-09 Impact factor: 2.882
Authors: R Hachamovitch; D S Berman; H Kiat; I Cohen; H Lewin; A Amanullah; X Kang; J Friedman; G A Diamond Journal: Am J Cardiol Date: 1997-08-15 Impact factor: 2.778
Authors: R Hachamovitch; D S Berman; H Kiat; C N Bairey; I Cohen; A Cabico; J Friedman; G Germano; K F Van Train; G A Diamond Journal: J Am Coll Cardiol Date: 1996-07 Impact factor: 24.094
Authors: D S Berman; R Hachamovitch; H Kiat; I Cohen; J A Cabico; F P Wang; J D Friedman; G Germano; K Van Train; G A Diamond Journal: J Am Coll Cardiol Date: 1995-09 Impact factor: 24.094
Authors: G V Heller; S D Herman; M I Travin; J I Baron; C Santos-Ocampo; J R McClellan Journal: J Am Coll Cardiol Date: 1995-11-01 Impact factor: 24.094
Authors: Olivier De Winter; Anja Velghe; Nico Van de Veire; Pieter De Bondt; Marc De Buyzere; Christophe Van De Wiele; Guy De Backer; Thierry C Gillebert; Rudi A Dierckx; Johan De Sutter Journal: J Nucl Cardiol Date: 2005 Nov-Dec Impact factor: 5.952
Authors: Roberta Green; Valeria Cantoni; Mario Petretta; Wanda Acampa; Mariarosaria Panico; Pietro Buongiorno; Giorgio Punzo; Marco Salvatore; Alberto Cuocolo Journal: J Nucl Cardiol Date: 2017-02-15 Impact factor: 5.952
Authors: Jane A Simonsen; Oke Gerke; Charlotte K Rask; Mohammad Tamadoni; Anders Thomassen; Søren Hess; Allan Johansen; Hans Mickley; Lisette O Jensen; Jesper Hallas; Werner Vach; Poul F Høilund-Carlsen Journal: J Nucl Cardiol Date: 2013-03-01 Impact factor: 5.952
Authors: Abdou Elhendy; Arend F l Schinkel; Ron T van Domburg; Jeroen J Bax; Roelf Valkema; Don Poldermans Journal: J Nucl Cardiol Date: 2003 Nov-Dec Impact factor: 5.952